DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR XTANDI
All Clinical Trials for Xtandi
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00510718 | A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer | Active, not recruiting | Medivation, Inc. | Phase 1 | 2007-07-01 | This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer. Additional patients will be enrolled in expanded cohorts at doses determined to be tolerable. Patients who tolerate the drug and do not progress will be allowed to continue to look for PSA response. |
| NCT01302041 | A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy | Active, not recruiting | Medivation, Inc. | Phase 2 | 2011-05-01 | To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer. |
| NCT01302041 | A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy | Active, not recruiting | Astellas Pharma Inc | Phase 2 | 2011-05-01 | To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer. |
| NCT01534052 | A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 | Active, not recruiting | Medivation, Inc. | Phase 2 | 2011-11-01 | A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit. |
| NCT01534052 | A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100 | Active, not recruiting | Astellas Pharma Inc | Phase 2 | 2011-11-01 | A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit. |
| NCT01597193 | Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer | Active, not recruiting | Astellas Pharma Inc | Phase 1 | 2012-04-01 | The purpose of this study is to determine the safety, tolerability and pharmacokinetics of enzalutamide alone and in combination with anastrozole, or exemestane, or fulvestrant in patients with incurable breast cancer. |
| NCT01597193 | Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer | Active, not recruiting | Medivation is now a wholly owned subsidiary of Pfizer Inc. | Phase 1 | 2012-04-01 | The purpose of this study is to determine the safety, tolerability and pharmacokinetics of enzalutamide alone and in combination with anastrozole, or exemestane, or fulvestrant in patients with incurable breast cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Xtandi
Condition Name
Clinical Trial Locations for Xtandi
Trials by Country
Clinical Trial Progress for Xtandi
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Xtandi
Sponsor Name
